



Bovine Viral Diarrhea/Mucosal Disease

Guest Editor:

Dr. Kerstin Wernike

Institute of Diagnostic Virology,
Friedrich-Loeffler-Institut, Federal
Research Institute for Animal
Health, 17493 Greifswald-Insel
Riems, Germany

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editor

Dear colleagues,

Bovine viral diarrhoea virus (BVDV), a flavivirus that exists in the two distinct species *Pestivirus A* and *Pestivirus B*, is endemic in cattle populations worldwide and causes major economic losses and has a significant impact on animal welfare. Hence, fetal protection against all circulating BVDV strains is a major benchmark of vaccination strategies, which might be complicated by the high genetic variability of the virus. Another point to bear in mind when developing anti-BVDV vaccines is their DIVA (differentiation of infected from vaccinated animals) capability, which could assist in ongoing eradication programs that have been implemented in several countries. This Special Issue will focus on the advances in the development of novel vaccines and vaccination strategies against BVD/MD. Besides, the use of vaccines highly depends on legal provisions and the epidemiological situation in a given area. Therefore, studies on the epidemiology of the disease are also welcome.

Dr. Kerstin Wernike
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)